Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.

[1]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Baselga,et al.  Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Rödel,et al.  Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. , 2000, International journal of radiation oncology, biology, physics.

[4]  Y. H. Lee,et al.  The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. , 2000, The Journal of urology.

[5]  P. Albers,et al.  p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy? , 2000, European journal of cancer.

[6]  C. Busch,et al.  Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas. , 1999, The Journal of urology.

[7]  V. Rotter,et al.  Mutant p53 protein expression interferes with p53-independent apoptotic pathways , 1998, Oncogene.

[8]  I. Tannock,et al.  Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Kuzel,et al.  Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[11]  M. Mazumdar,et al.  Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Parodi,et al.  p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. , 1997, Cancer research.

[13]  O. Nativ,et al.  Anti‐neoplastic activity of paclitaxel on experimental superficial bladder cancer: In vivo and in vitro studies , 1997, International journal of cancer.

[14]  Peter A. Jones,et al.  p53 and treatment of bladder cancer , 1997, Nature.

[15]  Bert Vogelstein,et al.  Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 , 1996, Nature.

[16]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[17]  C. Cordon-Cardo,et al.  Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. , 1995, The Journal of urology.

[18]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[19]  D. Neuberg,et al.  Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Clarke,et al.  c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Ceribelli,et al.  Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Groshen,et al.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. , 1993, The American journal of pathology.

[23]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[24]  M. Clarke,et al.  Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells , 1993, Molecular and cellular biology.

[25]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Sugimura,et al.  Frequent association of p53 gene mutation in invasive bladder cancer. , 1992, Cancer research.

[27]  D. Neal,et al.  Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. , 1991, British Journal of Cancer.

[28]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[29]  A. Levine,et al.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. , 1991, Genes & development.

[30]  M. Oren,et al.  Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein , 1991, Molecular and cellular biology.

[31]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[32]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[33]  M. Benson,et al.  Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. , 1989, Urology.

[34]  T. Lawrence,et al.  The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization , 2000, Cancer Chemotherapy and Pharmacology.

[35]  C. Cordon-Cardo,et al.  Can p53 help select patients with invasive bladder cancer for bladder preservation? , 1999, The Journal of urology.

[36]  M. Weller,et al.  Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status , 1999, Cancer Chemotherapy and Pharmacology.

[37]  S. Schwartz,et al.  p53 mutations in bladder carcinoma cell lines. , 1994, Oncology research.